Although the fund owns companies across the health care sector, including insurers and
equipment makers, a pharmaceutical - heavy portfolio — about 60 % of Health Care's assets are invested in pharmaceutical and
biotech firms — held the fund back over the past year as those stocks came under fire during the recent U.S. presidential campaign.